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Peripheral arterial disease (PAD) is a highly prevalent public health problem associated with major detrimental effects on
quality of life and functional status, and it is also the main cause of limb amputation. More importantly, PAD has been
classified as a coronary artery disease equivalent, meaning that patients with a diagnosis of PAD carry a risk for major
coronary events equal to that of established coronary artery disease. PAD is also a potent predictor of stroke and death.
Despite its frequent occurrence (8 to 10 million Americans are affected), little is known about the natural history of PAD
in racial/ethnic minorities, particularly inHispanics, who represent 12.5% of the United States population. Furthermore,
the disease is commonly underdiagnosed and undertreated in this minority group, and outcomes are poorer in Hispanics
as compared with whites. Limited access to health care, difficulties for recruitment in population-based studies, and
limitations of the noninvasive screening tests are well-established barriers to determine the prevalence and natural history
of PAD in Hispanics. Although the most widely used test for assessment of patients at risk for PAD is the ankle-brachial
index (ABI), the test has substantial limitations in individuals with diabetes and arterial calcification, which are highly
prevalent in Hispanics. The ABI should, therefore, be supplemented by the use of other noninvasive tests, such as the
pulse volume recordings (PVR) and toe-brachial index. Besides the use of a combination of diagnostic techniques, the
implementation of a research methodology that improves recruitment of Hispanics in population-based studies is
necessary to obtain better knowledge of the epidemiology of the disease in this group. Community-based participatory
research may be the most appropriate approach to study this ethnic minority because it overcomes barriers for limited
access to health care and increases the possibility of overcoming distrust of research on the part of communities.
Understanding the epidemiology of PAD to improve its detection and treatment among Hispanics is relevant to reduce
disparities in the health status of this group, the most rapidly growing ethnic minority in the United States. ( J Vasc Surg
2010;51:27S-35S.)EPIDEMIOLOGY AND NATURAL HISTORY OF
PERIPHERAL ARTERIAL DISEASE
Although in a broad sense the term peripheral arterial
disease (PAD) encompasses a large series of disorders that
affect arterial beds exclusive of the coronary arteries, for the
purpose of this review, PAD refers to atherosclerotic occlu-
sive disease of the arterial system of the lower extremities
(ie, the infrarenal aorta and/or arteries distal to the aortic
bifurcation).1 PAD is a highly prevalent public health prob-
lem affecting 8 to 10 million Americans and up to 29% of
individuals age 55 or older.1-4 Because PAD is a marker of
systemic atherosclerosis, which also includes coronary and
cerebrovascular artery disease, individuals with PAD have a
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events and a three-fold increased short-termmortality com-
pared with age-matched individuals (Fig).1,2,5-8 PAD is
also associated with a major detrimental effect on quality of
life, particularly when individuals with lower extremity
PAD present with atypical pain or intermittent claudication
(ie, the occurrence of calf, hip, and/or buttock pain or
discomfort on walking that is relieved with rest).1,3,9,10
Individuals with PAD thus experience a more rapid func-
tional decline and impairment of leg function, which fre-
quently result in significant loss of mobility and ability to
perform daily living activities.11,12 As the population ages
and its oldest segment expands, the prevalence of PAD and
its associated disability will certainly result in increased
health care burden and expenditures.
The prevalence of PAD in the general population in
individuals older than 55 years has been estimated to be
between 3% and 29%.5,6,13,14 These data are, however,
based on population-based studies including predomi-
nantly non-Hispanic white individuals. The prevalence of
PAD rises with age and has been found to be approximately
20% in people over 70 years of age5,6,13-15 and up to 60% in
the over 85-year age group.6 Although previous studies
have shown variations in the prevalence of this disease
among different ethnic groups,16-20 the prevalence of PAD
in Hispanic populations, however, has not been extensively
studied. The purpose of this article is to provide an over-
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methods, and treatment of PAD in Hispanics as well as the
limitations and possible approaches to improve its detec-
tion and management.
HISPANICS IN THE US POPULATION
Hispanics represent 12.5% (35 million) of the US pop-
ulation according to the 2000 US census. Most Hispanics
indicated their race category as white (47.9%) or “some
other race” (42.2%) in the census questionnaire. By 2050,
an estimated 102millionHispanics will reside in theUnited
States, nearly 24.5% of the total US population.21 Current
health policies in the US, contained in the Healthy People
2010 initiative, insist on improving quality of life and elim-
inating racial and ethnic disparities in health status as the
two primary goals.22 Such objectives can only be fulfilled if
complete understanding of PAD in different ethnic groups
is achieved.9 Moreover, the effects of acculturation and
socioeconomic factors on the prevalence and severity of
PAD need to be investigated. If Hispanics experience
poorer health status, this expected demographic change
will magnify the adverse economic, social, and health im-
pact of such disparities.23 A critical need of research studies
exists to define the true prevalence and natural history of
PAD inHispanics. Moreover, immediate action to enhance
health promotion and lifestyle changes is also required.
PREVALENCE OF PAD IN HISPANICS
Differences in the evolution and prevalence of PAD
across ethnic groups have been demonstrated. However,
most available observational studies assessing PAD among
Hispanics have included primarily hospital-based and clin-
ical settings, which are prone to individual selection bias.
Few population-based studies have examined the relation-
ship between race/ethnicity and lower-extremity PAD.
Prevalence estimates for Hispanics have varied widely, with
Fig. Natural history of peripheral arterial disease (PAD). Data have
been derived from studies that have included primarily non-Hispanic
white populations. Leg refers to the impact of PAD on lower
extremity symptoms and prognosis. Survival refers to the effect of
the disease on the patient’s mortality, which is related to the
increased risk of stroke and cardiac events.rates in the range of 1.8% to 13.7%.2,17,18 In a report fromthe National Health and Nutrition Examination Survey
(NHANES), non-Hispanic blacks had the highest preva-
lence of PAD, whereas Mexican Americans had levels that
were higher than whites but lower than blacks.20 Similarly,
the San Antonio Heart Study reported 61% greater odds of
PAD among Mexican Americans than among non-His-
panic whites.24 Conversely, two recent population-based
studies revealed opposite findings. The Multi-Ethnic Study
of Atherosclerosis (MESA) confirmed results from the San
Diego Population Study, which evaluated non-Hispanic-
whites, African-Americans, Hispanics, and Asians, found a
significant excess of PAD in blacks independent of tradi-
tional vascular risk factors and lower prevalence in Hispan-
ics.17,25,26 However, these two studies have important
limitations regarding the generalizability of their results
to the general population. In the MESA study, individ-
uals with cardiovascular disease were excluded, whereas
in the San Diego Population Study, only university em-
ployees with health insurance were included. Moreover,
individuals with an ankle-brachial index (ABI) greater
than 1.4 were excluded from the analysis in the MESA
study, which could have eliminated individuals with
PAD with vascular calcification. All the barriers that limit
the access of the Hispanic population to the health care
system have played a role in the difficulties found by the
investigators to determine the true prevalence of PAD in
this ethnic group.
DIAGNOSIS OF PAD
Medical history
The natural history and clinical presentation of PAD
need to be considered for its early recognition. Unfortu-
nately, ethnic differences in the natural history of PAD have
not been established. As with most atherosclerotic diseases,
in its early phases PAD is asymptomatic and only 9% to11%
of persons with PAD have the classic symptoms of intermit-
tent claudication (ie, the occurrence of calf, hip, and/or
buttock pain or discomfort on walking that is relieved with
rest).1,3,9,10 Critical limb ischemia (ie, the presence of pain
at rest or ischemic nonhealing ulcerations and gangrene)
represents only 1% of the general population older than age
50.1,3,9,10Whether these clinical presentations apply also to
Hispanics is unknown. The diagnosis of PAD based only on
clinical findings is, therefore, inadequate.
Noninvasive techniques for screening and detecting
PAD
Ankle-brachial index. Diagnostic intra-arterial an-
giography is the gold standard test for the diagnosis of
PAD, which is anatomically and angiographically defined as
occlusion or stenosis of 50% or more in a major leg ar-
tery.27,28 Because angiography is an invasive procedure
with inherent risk, discomfort, and cost, noninvasive arte-
rial studies are used preferentially to detect PAD. The most
widely used definition of PAD in epidemiologic studies is a
resting ABI of less than 0.90 (ie, the ratio of the ankle
systolic blood pressure and the higher of the two brachial
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cut point is generally accepted, the actual diagnostic value
of this threshold in the general population including differ-
ent ethnic groups is unclear. In a subgroup of participants
of MESA with normal ABIs (1.00 to 1.30), it was found
that gender and ethnicity were independently associated
with ABI.29 In this cohort of 1775 healthy subjects, the
ABI was about 0.02 lower in women than men and 0.02
lower in blacks compared with whites. These findings raise
the question whether a single threshold for all gender/
ethnic groups is then appropriate. Nevertheless, ABI values
have important prognostic implications. Low ABI values
have been associated with an increased risk of coronary
artery disease, stroke, and cardiovascular death.30 Even
borderline ABI values (ABI 0.90 to 0.99) and low normal
ABI values (ABI 1.00 to 1.09) have been associated with
higher prevalences of subclinical coronary and cerebrovas-
cular atherosclerosis as compared with an ABI of 1.10 to
1.30. Similarly, intermittent claudication, atypical exer-
tional leg pain, and the incidence of mobility loss are more
frequent among subjects with borderline ABI values than
among those with ABI values of 1.10 to 1.40.31,32
The sensitivity of the ABI is 90%, and the specificity is
98% for an angiographically defined stenosis of 50% or
more in a major leg artery according to small observational
studies of patients with established PAD assessed prior to
treatment.33 The ABI may, however, underestimate the
severity of disease in individuals with calcified, non-
compressible arteries. Advanced calcific atherosclerosis of
vessels beneath the cuff resists compression that results in
falsely elevated ankle–brachial pressure indices (ABI 
1.30).34,35 This calcification in the arterial walls is frequent
in diabetics and in individuals with chronic renal failure or
advanced age. As diabetes is highly prevalent among His-
panics, the use of ABI to detect the prevalence of PAD in
this population may not be accurate. Alternative arterial
studies, such as the toe-brachial index (TBI) and pulse
volume recording measurement, have been suggested to
detect PAD in individuals who are at risk for lower extrem-
ity PAD and have an ABI greater than 1.30.33 Most epide-
miologic studies, however, have excluded individuals with
ABI greater than 1.3, which clearly underestimates the true
prevalence of PAD, as angiographically defined stenosis of
50% or more in major leg arteries may occur in the presence
of severe calcification and high ABI.8,33
TBI. This test is performed by placement of a small
occlusive cuff on the proximal portion of the great or
second toe using plethysmography to detect the return of
toe pulsatility, which is a function of the systolic perfusion
pressure. The TBI is calculated as the ratio of the toe
systolic blood pressure and the higher of the two brachial
systolic pressures. In individuals with noncompressible ar-
terial segments, which are frequent in diabetics andHispan-
ics, the ABI is spuriously elevated, and values in the normal
range or greater than 1.3 may be obtained in the presence
of PAD. In such individuals, diagnostic information to
confirm or rule out the presence of PAD should be ob-
tained by the measurement of the TBI. TBI values less than0.7 are usually considered diagnostic for lower extremity
PAD.36,37 A recent study using ABI and TBI to evaluate
the presence of PAD in 510 ambulatory patients (37%
diabetics) revealed that ABI values  1.40 were signifi-
cantly associated with occlusive PAD. Of all the traditional
cardiovascular risk factors, diabetes was the dominant risk
factor for a high ABI.38 TBI should therefore always be
obtained in diabetics, as digital arteries are usually spared
the calcinosis that alters compressibility of more proximal
arteries. In another recent study on 1762 patients referred
to a vascular clinic because of PAD symptoms, the preva-
lence of elevated ABI was 8.4%. In the subset of patients
with elevated ABI, the prevalence of PAD defined as a TBI
0.60 was 78.2% among subjects with an ABI  1.4 and
83.5% among those with an ABI  1.5.39 According to a
recent report from the American Heart Association Statis-
tics Committee and Stroke Statistics Subcommittee, the prev-
alence of physician-diagnosed diabetes among Hispanics liv-
ing in the USA is 11.1%, 11.3% for Mexican American
males, and 14.2% forMexican American females,40 which is
about two times higher than that in non-Hispanic whites
and similar to that in non-Hispanic blacks (Table I). Fur-
thermore, the prevalence of fasting glucose greater than
126 mg/dL in Mexican-American men unaware of being
diabetic is much higher than that in non-Hispanic whites
(6.0% vs 3.6%, respectively). The prevalence of diabetes
increases with age, and it is estimated to be about 34% in
Hispanics older than 65 years.41 The current total preva-
lence of diabetes in the United States for all age, gender,
and race/ethnicity groups is about 5.6%. However, by the
year 2050, it is expected to increase to 12.0%. Increases are
Table I. Prevalence of diabetes mellitus by
race/ethnicity and gender
Population group
Prevalence of
physician-
diagnosed
DM
Prevalence of
undiagnosed
DM
Prevalence of
prediabetes
Non-Hispanic white
Men 5.8% 3.6% 32.0%
Women 6.1% 2.2% 18.7%
Non-Hispanic black
Men 14.9% 4.7% 22.9%
Women 13.1% 3.1% 19.0%
Mexican Americans
Men 11.3% 6.0% 28.5%
Women 14.2% 1.9% 23.6%
Undiagnosed Diabetes mellitus (DM) is defined here as those whose fasting
glucose is 126 mg/dL but who did not report being told by a healthcare
provider that they had DM.
Prediabetes is a fasting blood glucose of 100 to 126 mg/dL (impaired
fasting glucose). Prediabetes includes impaired glucose tolerance.
Sources: Prevalence: Prevalence of diagnosed and undiagnosed diabetes:
NHLBI computations from NHANES 2003-2006; extrapolation to the
2006 US population.
Prevalence of prediabetes: CDC Fact Sheet.43 CDC computations are from
NHANES 2003-2006; extrapolation to the 2007 US population. Percentages
for racial/ethnic groups are age-adjusted for Americans20 years of age.projected to be the largest for Hispanics (127%) as com-
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blacks (107%).42 These data suggest that for the assessment
of PAD in epidemiologic studies in elder Hispanic popula-
tions, the traditional ABI technique should be supplemented
by the use of other noninvasive tests such as the TBI.
Pulse volume recordings. Pulse volume waveform
analysis measurements are performed with a system that
incorporates a pneumoplethysmograph (pulse volume re-
corder [PVR]). Pulse volume recordings are obtained using
standard blood pressure cuffs at the thigh, calf, and ankle.
Sensitive transducers detect small increases in pressure
within the cuffs. These increases are caused by a slight
increase in the volume of the extremity during systole. The
resulting recording closely resembles arterial pressure wave
tracings. The amplitude of the pulse volume wave reflects
local arterial pressure, vascular wall compliance, the num-
ber of arterial vessels beneath the cuff, and the severity of
atherosclerotic disease. A normal waveform has the follow-
ing characteristics: sharp upstroke, tall systolic peak, pres-
ence of a dicrotic notch, and rapid runoff to baseline or
narrow waveform. As the artery becomes more diseased,
the waveforms change accordingly, first losing the dicrotic
notch and then becoming wider and flatter.43,44 PVRs can
be measured easily and rapidly with the use of new FDA-
approved portable computerized devices. However, to our
knowledge, there are no community-based studies examin-
ing this technique to assess the prevalence of PAD in
Hispanic populations. In non-Hispanic populations, com-
munity-based detection of PAD using PVRs may not be
necessary, given the established accuracy of the ABI for
PAD detection and the adequate access to health care
among these populations that to some extent obviates the
need for community-based screening. PVRs have the ad-
vantage of revealing distortions in pulse wave contour even
in individuals with vascular calcification and may allow the
detection of PAD when ABI is within normal range or
greater than 1.3.45 The addition of PVRs to the ABI and
TBI for detection of PAD may decrease the false-positive
results that could potentially occur when the ABI or the
TBI are used exclusively for this purpose. A clear advantage
of an accurate detection of PAD would be the avoidance of
potential harms of screening, including false-positive re-
sults, labeling, and the adverse events associated with inva-
sive testing. Moreover, the harms of unnecessary or exces-
sive medical, interventional, and surgical treatment and
their adverse events could potentially be reduced or elimi-
nated by improving the accuracy of the screening tests.
Risk factor modification and treatment of PAD
In general, risk factors for PAD are similar to those for
cardiovascular disease. PAD, in fact, shares a common
atherosclerotic etiology with coronary artery and cerebro-
vascular disease. Of known risk factors, smoking is by far
the most important, as smokers have a 7.5-fold increased
risk of cardiovascular disease compared with nonsmokers.1,33
Nevertheless, the prevalence of cigarette smoking among
Mexican-American men and women is lower than that in
other racial/ethnic groups (Table II). Other risk factorsinclude diabetes, age, hyperlipidemia, renal failure, and
hypertension. In Hispanics with PAD, the prevalence of
tobacco smoking is lower, and the prevalence of diabetes is
higher than those in non-Hispanic whites and blacks with
PAD,46 suggesting that diabetes is a stronger risk factor for
PAD among Hispanics. Risk factor modification and con-
trol are effective forms of prevention. However, because
age may not be modified, PAD will invariably continue to
occur and affect the elderly. Additionally, since the preva-
lence of smoking among adults in the US remains approx-
imately 25%, and the incidence and prevalence of diabetes
continue to increase, it is estimated that a significant per-
centage of the US population, including Hispanics, will
continue to be affected by PAD.33
The devastating effects of lower-extremity PADmay be
preventable. The efficacy of interventions to prevent PAD is
not well known, but exercise training, smoking cessation,
aspirin and antiplatelet therapy, and lipid-lowering drugs
may each be effective in managing the condition.8 Effective
risk factor modification and control in individuals with
PAD may also reduce associated cardiovascular morbidity
and mortality.8 Consequently, smoking cessation and ef-
fective treatment of diabetes, hyperlipidemia, and hyper-
tension should be pursued in all individuals with PAD. The
presence of PAD may also be an indication for broad
management of vascular risk factors because of its associa-
tion with stroke, myocardial infarction, and cardiovascular
mortality. In fact, current cardiovascular risk stratification
guidelines from the National Cholesterol Education Pro-
gram (NCEP) Adult Treatment Panel report (ATP III)
classify PAD as a coronary heart disease equivalent, mean-
ing that patients with a diagnosis of PAD carry a risk for
major coronary events equal to that of established coronary
heart disease (ie, 20% per 10 years).47 Nevertheless, studies
Table II. Estimated prevalence of cigarette smoking
among adults aged  18 years by gender and
race/ethnicity
Population group
Prevalence of
cigarette
smoking (%)
95% confidence
interval
Non-Hispanic white
Men 23.1 21.6-24.6
Women 19.8 18.7-20.9
Non-Hispanic black
Men 24.8 22.0-27.6
Women 15.8 13.7-17.9
Hispanic
Men 18.0 15.5-20.5
Women 8.3 6.7-9.9
Non-Hispanic American
Indian/Alaska Native
Men 36.7 19.9-54.5
Women 36.0 20.2-51.8
Source: CDC. Cigarette smoking among adults—United States, 2007.
MMWR 2008;57:1221-26. Available at: http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm5745a2.htm.suggest that individuals with PAD are less aggressively
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recent prospective cohort study established that among
individuals with established arterial disease or with multiple
risk factors for atherosclerosis, individuals with PAD expe-
rienced the highest rate of cardiovascular death and major
cardiac events and stroke.48 Despite the increased cardio-
vascular risk associated with PAD, this disease is commonly
underdiagnosed and undertreated.33,49,50 Continuous su-
pervised and compliance enhancement programs within the
community have the potential to improve the treatment
and outcomes of PAD, particularly among Hispanics.
Exercise therapy for patients with PAD
Individuals with PAD do benefit from exercise therapy.
A recent Cochrane review of 10 randomized trials of exer-
cise therapy estimated an overall improvement in walking
distance of about 150% in individuals with intermittent
claudication, the classic form of symptomatic PAD.51 The
exercise component in all but one of these trials was super-
vised. In a meta-analysis of 18 randomized and nonran-
domized trials, the greatest benefit was associated with
continued walking until pain was nearly maximal and with
sessions that lasted longer than 30 minutes, took place
three or more times per week, and continued for at least 6
months.52 Others have recently reported that higher phys-
ical activity levels during daily life are associated with less
functional decline among people with PAD.53 Although
few randomized trials have directly compared supervised
and unsupervised exercise training, several observational
studies have failed to show significant functional improve-
ment with unsupervised exercise consisting of advice
alone.54,55 Of interest, the latest American College of
Cardiology/American Heart Association (ACC/AHA)
Guidelines for the management of PAD suggest that tread-
mill exercise appears to be more effective than other exer-
cise modalities, presumably because “treadmill walking
most closely reproduces walking in the community set-
ting.”33 No specific recommendation for community-
based walking programs was, however, included within the
Guidelines.
In addition to symptomatic improvements, exercise
also has the potential to reduce cardiovascular risk. Physical
inactivity is indeed an independent risk factor for cardiovas-
cular events, whereas exercise can favorably improve lipid
profile and glucose metabolism and reduce blood pres-
sure.56 Nevertheless, a recent report on national statistics
on heart disease and its risk factors revealed that Hispanic
adults were more likely not to engage in vigorous activity
(71.8%) than non-Hispanic adults (59.5%).40 Recent data
from the National Center for Health Statistics reveal that
Hispanics report higher levels of physical inactivity as
compared with non-Hispanic whites and non-Hispanic
blacks.57 Similarly, the proportion ofHispanics engaging in
at least one session of light/moderate or vigorous physical
activity of at least 10 minutes, duration, or in regular
leisure-time activity defined as three or more sessions per
week of vigorous activity lasting at least 20 minutes or five
ormore sessions per week of light/moderate activity lastingat least 30 minutes in duration was lower than the propor-
tion of non-Hispanic whites and blacks engaging in similar
activities (Table III). Community-driven walking programs
could be a mechanism to encourage physical activity and
improve cardiovascular fitness among minority groups. To
our knowledge, however, those programs have not been
investigated or reported.
Pharmacologic therapy for PAD
Pharmacologic therapy for PAD is primarily tailored to
meet current guidelines for risk factor modification.58 Cur-
rent evidence demonstrates that PAD symptoms, walking
distance, and quality of life can be improved by smoking
cessation (physician advice, nicotine replacement therapy,
and bupropion), cilostazol, and angiotensin-converting en-
zyme inhibitors.58 Statin drugs in particular have demon-
strated benefit in improvement in claudication symptoms,
ambulatory ability, total walking distance, and leg function-
ing59,60 even after adjustment for confounders.61 The risk
of major cardiac and cerebrovascular events can also be
further reduced through lowering blood pressure with
angiotensin-converting enzyme inhibitors and other anti-
hypertensive drugs, use of statins, antiplatelet therapy with
aspirin or clopidogrel, and probably by stopping smoking.
Beta-blockers are effective as antihypertensive therapy and
are not contraindicated in individuals with PAD. Antiplate-
let therapy with aspirin (75mg to 325mg daily) reduces the
risk of death from coronary events and stroke in individuals
with cardiovascular diseases by 25% and is recommended
for individuals with PAD.58 Currently two drugs, pentoxi-
fylline and cilostazol, have been approved by the FDA for
the treatment of intermittent claudication, which is only
manifested by a small proportion of individuals with
PAD.3,58 Although the pharmacologic treatment of PAD is
well-established, the frequency and adequacy of these ther-
apies among Hispanics are unknown.
Recent epidemiologic data reveal ethnic disparities in
the prevention and treatment of other cardiovascular dis-
Table III. Leisure-time physical activity among adults 18
years of age and over, by selected characteristics: United
States, 2006
Population group Inactive
Some
leisure-time
activity
Regular
leisure-time
activity
Hispanic or Latino 53.4 (1.1) 23.8 (0.9) 22.8 (0.9)
Mexican 53.9 (1.5) 24.2 (1.1) 22.0 (1.2)
Not Hispanic or Latino 37.3 (0.7) 30.4 (0.5) 32.3 (0.5)
White only 35.3 (0.7) 31.0 (0.5) 33.8 (0.6)
Black or African
American only
49.0 (1.3) 26.4 (1.0) 24.7 (1.0)
Values are presented as percentage (standard errors).
Source: CDC/NCHS, National Health Interview Survey, family core and
sample adult questionnaires.
Reference: Health, United States, 2008 with Chartbook. Hyattsville, MD:
National Center for Health Statistics; 2009.eases related to PAD and that Hispanics are much less likely
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lipid abnormalities and other cardiovascular risk factors. A
study using data from the Third National Health and
Nutrition Examination Survey revealed that African Amer-
icans and Mexican Americans were less likely to report
serum cholesterol screening than whites. Even when iden-
tified as having high cholesterol that required medication,
African Americans and Mexican Americans were less likely
than whites to be taking cholesterol-lowering agents.62
In the San Antonio Heart Study, Mexican-Americans
were less likely than whites to be aware of and to be
undergoing treatment for high cholesterol.63 In the 1988-
1990 Behavioral Risk Factor Surveillance System (BRFSS),
African Americans and Hispanics were less likely than
whites to report cholesterol screening.64
Endovascular and surgical treatment of PAD
Revascularization (endovascular or surgical) therapy is
reserved for lifestyle-limiting claudication and lack of re-
sponse to exercise or pharmacotherapy whenever the risk-
benefit ratio with revascularization is favorable. Endovas-
cular treatments are minimally invasive catheter-based
procedures, which include primarily percutaneous translu-
minal angioplasty (PTA) with or without stenting. Surgical
revascularization is reserved for more advanced forms of
PAD, usually when limb-threatening ischemia develops.33
Both surgical revascularization and PTA are effective in
improving ABI values, functional status, walking ability,
and quality of life in patients with claudication.65,66 A
prospective, observational study in 60 patients undergoing
surgical bypass grafting and 44 patients undergoing PTA
demonstrated that the ABI increased an average of 0.36 in
the open bypass group and 0.23 in the PTA group. Over an
18-month follow-up period, both groups had similar im-
provement in physical functioning and walking.65 A second
prospective study looking at quality-of-life outcomes in
patients treated with PTA for claudication and critical limb
ischemia revealed that after 1 year of follow-up, mainte-
nance of independence and ambulation status along with
other daily physical functions was significantly improved.66
Although multiple factors such as young age, diabetes
mellitus, and smoking play a role in early graft failure, there
is some evidence that race may have an effect on the
durability of lower extremity revascularization. In a large
retrospective review of almost 15,000 patients undergoing
lower extremity revascularization, it was found that the rate
of early graft failure was higher in blacks as compared with
Caucasians (6.7% vs 4.5% respectively).67 In fact, blacks are
found to be 1.7 times more likely to undergo primary and
repeat amputation than Caucasians.68 Although more at-
tention has been given recently to PAD and outcomes of
minorities,69 few studies have tried to look at Hispanics
separately. A recent multiethnic study of infrainguinal by-
pass for patients with claudication, rest pain, and tissue loss
revealed that after a mean follow-up period of 18 months,
Hispanics and blacks showed poorer outcomes.70 The pa-
tency rate was 46.9% and 59.9% for Hispanics and Cauca-
sians, respectively, while the limb salvage rate was 72.6%and 90.8% for Hispanics and Caucasians, respectively. In-
terestingly, most Hispanic patients were treated for tissue
loss (86%) and had a higher incidence of diabetes mellitus.
A second study attempted to more selectively compare the
differences in treatment and outcomes of Hispanics and
Caucasians for PAD.71 Patients who underwent lower ex-
tremity revascularization with diagnoses of rest pain, ulcer-
ation, and gangrene were included in the limb-threatening
group. Hispanics were significantly more likely to present
with limb-threatening ischemia. In addition, these patients
tended to have poorly controlled diabetes and experienced
function-limiting pain starting at a younger age. Both
factors are associated with more advanced presentation,
resulting in limited therapeutic options (ie, PTA) and an
increased likelihood to undergo a primary amputation.
Finally, a more recent study that compared the results of
autogenous infrainguinal bypass grafting in a multiethnic
cohort of 1646 patients provided evidence of inferior out-
comes in Hispanics treated for PAD.72 Hispanics had lower
rates of primary patency and limb salvage than whites
despite similar rates of critical limb ischemia, and Hispanic
ethnicity was an independent predictor of limb loss.
Although current evidence reveals that Hispanic patients
with lower extremity arterial disease exhibit poor outcomes
after revascularization, little data exist to explain possible dif-
ferences related to type of repair, open surgical bypass vs
PTA/stenting. This question may remain until the classic
clinical picture changes: fewer patients presenting with ad-
vanced arterial limb disease. Although to some extent, the
problem seems to fall back to socioeconomic factors (ie,
limited education and access to proper preventative and diag-
nostic care), recent evidence indicates that ethnic and racial
differences in the natural history of PAD may still occur after
adjusting for socioeconomic differences or when these are
nonexistent.73,74 Small improvements may, however, change
the overall Hispanic population presenting with vascular dis-
ease, thereby resulting in earlier diagnosis with more thera-
peutic options and better outcomes.
CLINICAL RESEARCH SUPPORTING
COMMUNITY-BASED INTERVENTIONS IN
HISPANICS
A community is commonly defined as a group of people
with diverse characteristics who are linked by social ties,
share common perspectives, and engage in joint actions in
geographical locations or settings. Community context has
been identified as an important determinant of health out-
comes. This fact has increased the interest in community
collaboration as an important strategy for successful clinical
research and public health programs.75 Community-based
participatory research (CBPR) is a collaborative process of
research involving researchers and community representa-
tives. In this process, community-based organizations or
groups (such as churches and other social organizations)
help researchers in different steps of the research project,
including recruitment of individuals.76
CBPR may be the most appropriate approach to study
ethnic minorities because it overcomes barriers for limited
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 9S Rosero et al 33Saccess to health care and increases the possibility of over-
coming distrust of research on the part of communities
that have historically been “subjects” of such research.77
Precedents for community-based trials of risk-factor
modification have been established in the prevention and
treatment of diabetes and cardiovascular disease. In a
study of Hispanic women comparing provider counsel-
ing and health education versus the combination of
counseling, education, and support from a lay health
promoter (LHP), individuals receiving a combined com-
munity and certified diabetes nurse educator interven-
tion were more likely to complete diabetes education
than controls;78 those receiving printed nutrition educa-
tion materials and LHP visits had lower total fat and
saturated fat than those receiving printed materials
alone,79 and attendance at annual health screening was
greater among Hispanics receiving an LHP visit com-
pared with those receiving a postcard-only reminder.80
Among African-American men, when an education and
referral intervention was compared with a team approach
consisting of a nurse practitioner, physician, and LHP,
the team approach decreased blood pressure and pro-
gression of left ventricular hypertrophy.81 Similarly, a
community-based nurse practitioner and LHP team low-
ered global cardiovascular risk among black families with
a history of premature coronary artery disease and in-
creased the likelihood of achieving target levels of low-
density lipoprotein cholesterol and blood pressure com-
pared with an enhanced primary care delivery method.82
In another study testing a team approach, those random-
ized to a nurse case manager and LHP team had im-
proved triglycerides and diastolic blood pressure com-
pared with those receiving usual care.83 Available
observational studies assessing vascular risk factors be-
tween Hispanics and other ethnic groups have included
primarily hospital-based and epidemiological studies,
which are prone to individual selection bias. Communi-
ty-based studies are necessary to convincingly answer the
important questions regarding vascular differences and
their treatment implications between ethnic and racial
minorities. To our knowledge, there are no studies that
evaluate PAD in Hispanic communities using a CBPR
approach. Recent research demonstrates, however, that
CBPR has been successfully used in other medical con-
ditions. A study revealed that the use of lay health
promoters was effective for addressing cardiovascular
disease risk factors among Hispanics living in the US-
Mexico border region. The implementation of this com-
munity-based intervention program revealed positive
changes in behavioral factors as well in low-density li-
poprotein cholesterol level, triglyceride level, waist cir-
cumference, diastolic blood pressure, weight, and gly-
cated hemoglobin among the participants.84 Other
studies have provided additional information about the
effectiveness of CBPR methodology and the role of lay
health workers for cardiovascular disease prevention and
prevention and treatment of diabetes mellitus among
Hispanics.78,85CONCLUSIONS
PAD is a prevalent major public health problem that
substantially affects quality of life and increases the risk of
cardiovascular events and stroke in all populations. Al-
though several epidemiologic studies have assessed the
prevalence and natural history of PAD among non-Hispanic
whites, and to a lesser extent in African-Americans, scarce
information is available about the disease in Hispanics.
Health disparities — the differences in incidence, preva-
lence, mortality, and burden of disease that exists among
specific population groups — persist in the US. The true
prevalence of PAD in Hispanics is unknown in part due to
the limited access of this ethnic group to the health care
system. In addition, the fact that the standard screening test
for PAD, the ABI, may not be reliable in individuals with
diabetes, which is highly prevalent in Hispanics, may signif-
icantly contribute to the imprecise estimate of the true
prevalence of PAD among this minority. A critical need of
research studies exists to define the true prevalence and
natural history of PAD in Hispanics.
Effective methods of improving functional outcomes and
quality of life in individuals with PADhave been documented.
As the population ages and the incidence of PAD increases,
therewill be an inevitable increase in the cost and utilization of
resources for the treatment of the disease. In Hispanics and
other minorities with limited access to health care, communi-
ty-based interventions such as supervised exercise therapy and
risk factor modification could potentially reduce the burden
and cost of the health care system.
AUTHOR CONTRIBUTIONS
Conception and design: CT, ER, GC
Analysis and interpretation: CT, ER, KK, GP
Data collection: CT, ER, KK
Writing the article: CT, ER, KK, GP
Critical revision of the article: CT, ER, KK, GP
Final approval of the article: CT, ER, KK, GP
Statistical analysis: CT, ER
Obtained funding: CT
Overall responsibility: CT
REFERENCES
1. Dormandy JA, Rutherford RB. Management of peripheral arterial dis-
ease (PAD). TASC Working Group. TransAtlantic Inter-Society Con-
sensus (TASC). J Vasc Surg 2000;31:S1-S296.
2. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S,
Goodman D. The prevalence of peripheral arterial disease in a defined
population. Circulation 1985;71:510-5.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager
MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and
treatment in primary care. JAMA 2001;286:1317-24.
4. McDermott MM, Kerwin DR, Liu K, Martin GJ, O’Brien E, Kaplan H,
et al. Prevalence and significance of unrecognized lower extremity
peripheral arterial disease in general medicine practice*. J Gen Intern
Med 2001;16:384-90.
5. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV,
Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and
symptomatic peripheral arterial disease in the general population. Int J
Epidemiol 1991;20:384-92.
JOURNAL OF VASCULAR SURGERY
April Supplement 201034S Rosero et al6. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE.
Peripheral arterial disease in the elderly: The Rotterdam Study. Arterio-
scler Thromb Vasc Biol 1998;18:185-92.
7. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and
mortality in hypertensive adults with a low ankle/arm blood pressure
index. JAMA 1993;270:487-9.
8. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbid-
ity and mortality implications. Circulation 2006;114:688-99.
9. Hirsch AT, Gloviczki P, Drooz A, Lovell M, Creager MA. Mandate for
creation of a national peripheral arterial disease public awareness pro-
gram: an opportunity to improve cardiovascular health. J Vasc Surg
2004;39:474-81.
10. Khaira HS, Hanger R, Shearman CP. Quality of life in patients with
intermittent claudication. Eur J Vasc Endovasc Surg 1996;11:65-9.
11. McDermottMM,Greenland P, Liu K, Guralnik JM, CriquiMH,Dolan
NC, et al. Leg symptoms in peripheral arterial disease: associated clinical
characteristics and functional impairment. JAMA 2001;286:1599-606.
12. McDermottMM,Hoff F, Ferrucci L, PearceWH,Guralnik JM, Tian L,
et al. Lower extremity ischemia, calf skeletal muscle characteristics, and
functional impairment in peripheral arterial disease. J Am Geriatr Soc
2007;55:400-6.
13. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al.
High prevalence of peripheral arterial disease and co-morbidity in 6880
primary care patients: cross-sectional study. Atherosclerosis 2004;172:95-
105.
14. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW.
Prevalence and clinical correlates of peripheral arterial disease in the
Framingham Offspring Study. Am Heart J 2002;143:961-5.
15. Regensteiner JG, Hiatt WR. Current medical therapies for patients with
peripheral arterial disease: a critical review. Am JMed 2002;112:49-57.
16. Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. Ethnicity
and peripheral arterial disease. Mayo Clin Proc 2005;80:48-54.
17. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et
al. Ethnicity and peripheral arterial disease: the San Diego Population
Study. Circulation 2005;112:2703-7.
18. McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF, et al.
Ankle-brachial index and subclinical cardiac and carotid disease: the
multi-ethnic study of atherosclerosis. Am J Epidemiol 2005;162:33-41.
19. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Preva-
lence and risk factors of peripheral vascular disease in a selected South
Indian population: the Chennai Urban Population Study. Diabetes
Care 2000;23:1295-300.
20. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial
disease in the United States: results from the National Health and Nutri-
tion Examination Survey, 1999-2000. Circulation 2004;110:738-43.
21. US Census Bureau. US Interim Projections by Age, Sex, Race, and
Hispanic Origin. Available at: http://www.census.gov/ipc/www/
usinterimproj. Accessed Apr 1, 2009.
22. Healthy People 2010 Goals. Available at: http://www.healthypeople.
gov/About/goals.htm. Accessed Apr 11, 2007.
23. NIH. Addressing Health Disparities: The NIH Program of Action.
Available at: http://healthdisparities.nih.gov/whatare.html. Accessed
Apr 24, 2007.
24. Haffner SM, Hazuda HP, Mitchell BD, Patterson JK, Stern MP.
Increased incidence of type II diabetes-mellitus in Mexican-Americans.
Diabetes Care 1991;14:102-8.
25. Criqui MH, Allison MA, McDermott MM, Liu K, Bertoni AG, Folsom
A, et al. Ethnic differences and risk factors for peripheral arterial disease
(PAD) in the multi-ethnic study of atherosclerosis (MESA). Circulation
2004;109:E78.
26. Allison MA, Criqui MH, McClelland RL, Scott JM, McDermott MM,
Liu K, et al. The effect of novel cardiovascular risk factors on the
ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic
Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006;48:1190-7.
27. Fowkes FG. The measurement of atherosclerotic peripheral arterial
disease in epidemiological surveys. Int J Epidemiol 1988;17:248-54.
28. Lijmer JG, HuninkMG, van den Dungen JJ, Loonstra J, Smit AJ. ROC
analysis of noninvasive tests for peripheral arterial disease. Ultrasound
Med Biol 1996;22:391-8.29. Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, Criqui MH.
The association between elevated ankle systolic pressures and peripheral
occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc
Surg 2008;48:1197-203.
30. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial
index to predict future cardiovascular outcomes: a systematic review.
Arterioscler Thromb Vasc Biol 2005;25:1463-9.
31. McDermott MM, Guralnik JM, Tian L, Liu K, Ferrucci L, Liao Y, et al.
Associations of borderline and low normal ankle-brachial index values
with functional decline at 5-year follow-up: the WALCS (Walking and
Leg Circulation Study). J Am Coll Cardiol 2009;53:1056-62.
32. Wang JC, Criqui MH, Denenberg JO, McDermott MM, Golomb BA,
Fronek A. Exertional leg pain in patients with and without peripheral
arterial disease. Circulation 2005;112:3501-8.
33. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin
JL, et al. ACC/AHA 2005 Practice Guidelines for the management of
patients with peripheral arterial disease (lower extremity, renal, mesen-
teric, and abdominal aortic): a collaborative report from the American
Association for Vascular Surgery/Society for Vascular Surgery, Society
for Cardiovascular Angiography and Interventions, Society for Vascular
Medicine and Biology, Society of Interventional Radiology, and the
ACC/AHA Task Force on Practice Guidelines (Writing Committee to
Develop Guidelines for the Management of Patients With Peripheral
Arterial Disease): endorsed by the American Association of Cardiovas-
cular and Pulmonary Rehabilitation; National Heart, Lung, and Blood
Institute; Society for Vascular Nursing; TransAtlantic Inter-Society
Consensus; and Vascular Disease Foundation. Circulation 2006;113:
e463-e654.
34. Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW.
Limitation of the resting ankle-brachial index in symptomatic patients
with peripheral arterial disease. Vasc Med 2006;11:29-33.
35. Taguchi JT, Suwangool P. “Pipe-stem” brachial arteries. A cause of
pseudohypertension. JAMA 1974;228:733.
36. Ramsey DE, Manke DA, Sumner DS. Toe blood pressure. A valuable
adjunct to ankle pressure measurement for assessing peripheral arterial
disease. J Cardiovasc Surg (Torino) 1983;24:43-8.
37. Carter SA, Tate RB. The value of toe pulse waves in determination of
risks for limb amputation and death in patients with peripheral arterial
disease and skin ulcers or gangrene. J Vasc Surg 2001;33:708-14.
38. Aboyans V, Criqui MH, McClelland RL, Allison MA, McDermott
MM, Goff DC Jr, et al. Intrinsic contribution of gender and ethnicity to
normal ankle-brachial index values: the Multi-Ethnic Study of Athero-
sclerosis (MESA). J Vasc Surg 2007;45:319-27.
39. Suominen V, Rantanen T, Venermo M, Saarinen J, Salenius J. Preva-
lence and risk factors of PAD among patients with elevated ABI. Eur J
Vasc Endovasc Surg 2008;35:709-14.
40. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB,
Flegal K, et al. Heart disease and stroke statistics--2009 update: a report
from the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation 2009;119:480-6.
41. McBean AM, Li S, Gilbertson DT, Collins AJ. Differences in diabetes
prevalence, incidence, and mortality among the elderly of four racial/
ethnic groups: whites, blacks, Hispanics, and Asians. Diabetes Care
2004;27:2317-24.
42. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact
of recent increase in incidence on future diabetes burden: U.S., 2005-
2050. Diabetes Care 2006;29:2114-6.
43. Symes JF, GrahamAM,MousseauM.Doppler waveform analysis versus
segmental pressure and pulse-volume recording: assessment of occlu-
sive disease in the lower extremity. Can J Surg 1984;27:345-7.
44. Teodorescu VJ, Chen C, Morrissey N, Faries PL, Marin ML, Hollier
LH. Detailed protocol of ischemia and the use of noninvasive vascular
laboratory testing in diabetic foot ulcers. Am J Surg 2004;187:75S-80S.
45. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek
A. Risk factors for progression of peripheral arterial disease in large and
small vessels. Circulation 2006;113:2623-9.
46. Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The preva-
lence of peripheral arterial disease in a racially diverse population. Arch
Intern Med 2003;163:1469-74.
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 9S Rosero et al 35S47. Lepor NE, Vogel RE. Summary of the third report of the National
Cholesterol Education Program Adult Treatment Panel III. Rev Car-
diovasc Med 2001;2:160-5.
48. Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother
J, et al. One-year cardiovascular event rates in outpatients with athero-
thrombosis. JAMA 2007;297:1197-206.
49. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et
al. Critical issues in peripheral arterial disease detection and manage-
ment: a call to action. Arch Intern Med 2003;163:884-92.
50. Diehm C, Lange S, Darius H, Pittrow D, von SB, Tepohl G, et al.
Association of low ankle brachial index with high mortality in primary
care. Eur Heart J 2006;27:1743-9.
51. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication.
Cochrane Database Syst Rev 2000;2.CD000990.
52. Gardner AW, Poehlman ET. Exercise rehabilitation programs for
the treatment of claudication pain. A meta-analysis. JAMA 1995;274:
975-80.
53. Garg PK, Liu K, Tian L, Guralnik JM, Ferrucci L, Criqui MH, et al.
Physical activity during daily life and functional decline in peripheral
arterial disease. Circulation 2009;119:251-60.
54. Currie IC, Wilson YG, Baird RN, Lamont PM. Treatment of intermit-
tent claudication: the impact on quality of life. Eur J Vasc Endovasc
Surg 1995;10:356-61.
55. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR.
Hospital vs home-based exercise rehabilitation for patients with periph-
eral arterial occlusive disease. Angiology 1997;48:291-300.
56. Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation
1999;99:963-72.
57. Health, United States, 2008 with Chartbook. Hyattsville, MD: Na-
tional Center for Health Statistics; 2009.
58. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of periph-
eral arterial disease. JAMA 2006;295:547-53.
59. Mohler ER, III, Hiatt WR, Creager MA. Cholesterol reduction with
atorvastatin improves walking distance in patients with peripheral arte-
rial disease. Circulation 2003;108:1481-6.
60. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et
al. Effects of simvastatin on walking performance and symptoms of
intermittent claudication in hypercholesterolemic patients with periph-
eral vascular disease. Am J Med 2003;114:359-64.
61. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH,
Liu K, et al. Statin use and leg functioning in patients with and without
lower-extremity peripheral arterial disease. Circulation 2003;107:
757-61.
62. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and
pharmacologic treatment of high serum cholesterol by race and ethnic-
ity: data from the Third National Health and Nutrition Examination
Survey. Arch Intern Med 2002;162:929-35.
63. Stern MP, Patterson JK, Haffner SM, Hazuda HP, Mitchell BD. Lack
of awareness and treatment of hyperlipidemia in type II diabetes in a
community survey. JAMA 1989;262:360-4.
64. Giles WH, Anda RF, Jones DH, Serdula MK,Merritt RK, DeStefano F.
Recent trends in the identification and treatment of high blood choles-
terol by physicians. Progress and missed opportunities. JAMA 1993;
269:1133-8.
65. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ.
Functional status and walking ability after lower extremity bypass graft-
ing or angioplasty for intermittent claudication: results from a prospec-
tive outcomes study. J Vasc Surg 2000;31:93-103.
66. Kalbaugh CA, Taylor SM, Blackhurst DW, Dellinger MB, Trent EA,
Youkey JR. One-year prospective quality-of-life outcomes in patients
treated with angioplasty for symptomatic peripheral arterial disease. J
Vasc Surg 2006;44:296-302.67. Singh N, Sidawy AN, DeZee KJ, Neville RF, Akbari C, Henderson W.
Factors associated with early failure of infrainguinal lower extremity
arterial bypass. J Vasc Surg 2008;47:556-61.
68. Feinglass J, Rucker-Whitaker C, Lindquist L, McCarthy WJ, Pearce
WH. Racial differences in primary and repeat lower extremity amputa-
tion: results from a multihospital study. J Vasc Surg 2005;41:823-9.
69. Kwolek CJ, Clagett GP. Changing demographics in patients with
vascular disease. J Vasc Surg 2009;49:528-31.
70. Rowe VL, Kumar SR, Glass H, Hood DB, Weaver FA. Race indepen-
dently impacts outcome of infrapopliteal bypass for symptomatic arterial
insufficiency. Vasc Endovascular Surg 2007;41:397-401.
71. Morrissey NJ, Giacovelli J, Egorova N, Gelijns A, Moskowitz A,
McKinsey J, et al. Disparities in the treatment and outcomes of vascular
disease in Hispanic patients. J Vasc Surg 2007;46:971-8.
72. Robinson WP 3rd, Owens CD. Inferior outcomes of autogenous in-
frainguinal bypass in Hispanics: an analysis of ethnicity, graft function,
and limb salvage. J Vasc Surg 2009;49:1416-25.
73. Baicker K, Chandra A, Skinner JS, Wennberg JE. Who you are and
where you live: how race and geography affect the treatment of medi-
care beneficiaries. Health Aff (Millwood) 2004;Suppl Web Exclusives:
VAR33-VAR44.
74. Chandra A. Who you are and where you live: race and the geography of
healthcare. Med Care 2009;47:135-7.
75. MacQueen KM,McLellan E,Metzger DS, Kegeles S, Strauss RP, Scotti
R, et al. What is community? An evidence-based definition for partici-
patory public health. Am J Public Health 2001;91:1929-38.
76. Community-Based Participatory Research. Available at: http://www.
ahrq.gov/about/cpcr/cbpr. Accessed April 1, 2007.
77. Israel BA, Schulz AJ, Parker EA, Becker AB. Community-based participa-
tory research: policy recommendations for promoting a partnership ap-
proach in health research. Educ Health (Abingdon) 2001;14:
182-97.
78. Corkery E, Palmer C, Foley ME, Schechter CB, Frisher L, Roman SH.
Effect of a bicultural community health worker on completion of diabetes
education in a Hispanic population. Diabetes Care 1997;20:254-7.
79. Elder JP, Ayala GX, Campbell NR, Slymen D, Lopez-Madurga ET,
Engelberg M, et al. Interpersonal and print nutrition communication
for a Spanish-dominant Latino population: Secretos de la Buena Vida.
Health Psychol 2005;24:49-57.
80. Hunter JB, de Zapien JG, Papenfuss M, Fernandez ML, Meister J,
Giuliano AR. The impact of a promotora on increasing routine chronic
disease prevention among women aged 40 and older at the U.S.-
Mexico border. Health Educ Behav 2004;31:18S-28S.
81. Hill MN, Han HR, Dennison CR, Kim MT, Roary MC, Blumenthal
RS, et al. Hypertension care and control in underserved urban African
American men: behavioral and physiologic outcomes at 36 months.
Am J Hypertens 2003;16:906-13.
82. Becker DM, Yanek LR, JohnsonWR, Jr., Garrett D,Moy TF, Reynolds
SS, et al. Impact of a community-based multiple risk factor intervention
on cardiovascular risk in black families with a history of premature
coronary disease. Circulation 2005;111:1298-304.
83. Gary TL, Bone LR, Hill MN, Levine DM,McGuire M, Saudek C, et al.
Randomized controlled trial of the effects of nurse case manager and
community health worker interventions on risk factors for diabetes-
related complications in urban African Americans. Prev Med 2003;37:
23-32.
84. Balcazar H, Alvarado M, Cantu F, Pedregon V, Fulwood R. A promo-
tora de salud model for addressing cardiovascular disease risk factors in
the US-Mexico border region. Prev Chronic Dis 2009;6:A02.
85. Artinian NT, Schim SM, Vander Wal JS, Nies MA. Eating patterns and
cardiovascular disease risk in a Detroit Mexican American population.
Public Health Nurs 2004;21:425-34.Submitted Jun 9, 2009; accepted Aug 23, 2009.
